Vietnam HIV Therapeutics Market Analysis Report [2022-30]

Vietnam HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam HIV therapeutics market will reach a value of $xx Mn from $68.8 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Vihado Joint Stock Company, Imexpharm Pharmaceutical, and Viet-AID. The market is driven by the management of HIV infections, high out-of-pocket expenditure, and the healthcare infrastructure of the country. The HIV therapeutics market in Vietnam is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10VNPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Vietnam HIV therapeutics market will reach a value of $xx Mn from $68.8 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Vietnam is a nation in Southeast Asia that borders the South China Sea, the Gulf of Tonkin, and the Gulf of Thailand. The Joint United Nations Program on HIV/AIDS set 90-90-90 targets in 2014, and Vietnam was the first nation in Asia to adopt them. The latest WHO data show that 4,993 people died from HIV/AIDS in Vietnam in 2020, or 0.73% of all deaths.

Vietnam is ranked 77th in the world by age-adjusted Death Rate, which is 4.72 per 100,000 of the population. In 2021, the adult prevalence of HIV/AIDS in Vietnam was 0.3%, placing the country in the 87th place globally. In 2019, Vietnam's GDP was allocated to healthcare at 4.7%.

vietnam HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers

Vietnam is one of four countries with the best HIV/AIDS treatment in the world along with Germany, the UK, and Switzerland. In Vietnam, 96% of HIV-positive individuals are receiving antiretroviral (ARV) therapy with viral loads below the inhibitory threshold, which helps lower the overall rate of HIV infection. Around 250,000 HIV patients are still alive in Vietnam, but only 210,000 of them are aware of their status, according to statistics from the health ministry.

Market Restraints

Since foreign donors began to stop supporting Vietnam's HIV/AIDS programs when it attained middle-income status, the country has had trouble raising money. The lowest cost of treatment for one HIV patient per year exceeds $172; however, the cost can be seven to eight times higher for those who are drug resistant. These factors may prevent new players from entering the Vietnam HIV therapeutics market.

Competitive Landscape

Key Players

Viet-AID (VNM)
Imexpharm Pharmaceutical (VNM)
Vihado Joint Stock Company (VNM)
Gilead Sciences
Pfizer
AstraZeneca
Novartis
GlaxoSmithKline

Healthcare Regulations and Reimbursement Policies

The Ministry of Health (MOH) is responsible for overseeing Vietnam's healthcare system, including the regulation of pharmaceuticals and medical devices. In order to increase access to antiretroviral (ARV) drugs and other HIV/AIDS-related services, the MOH collaborates with numerous partners, including international organizations and non-governmental organizations, to develop and implement policies and programs. All ARV medications used in the nation must adhere to these standards, and the MOH closely collaborates with the Vietnam Food and Drug Administration (VFDA) to make sure of this.

Vietnamese Social Insurance (VSI), the country's national health insurance program, primarily covers the cost of HIV therapeutics in Vietnam. The VSI provides coverage for a variety of medical services, including antiretroviral (ARV) therapy for HIV-positive individuals. At specific public health facilities, patients who are covered by the VSI can receive ARV medications.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.